Targeting Biomarkers and the FDA's Biomarker Qualification Framework [0.03%]
生物标志物的靶向及美国食品药品管理局的生物标志物认定框架
Hamed Ekhtiari,Arshiya Sangchooli,Alex Fornito et al.
Hamed Ekhtiari et al.
Kurt Kroenke
Kurt Kroenke
Josip Razum,Margarita Panayiotou,Zachary D Cohen
Josip Razum
Age at First Attention-Deficit/Hyperactivity Disorder Diagnosis and Educational Outcomes [0.03%]
首次注意缺陷多动障碍诊断年龄与教育成果的关系
Lotta Volotinen,Hanna Remes,Pekka Martikainen et al.
Lotta Volotinen et al.
Importance: Early diagnosis of attention-deficit/hyperactivity disorder (ADHD) is often recommended, but it is unknown whether age at diagnosis is associated with educational outcomes. ...
General Anesthesia and Discrete Components of Ketamine Neurophysiology [0.03%]
有关异丙酚和氯胺酮神经生理学成分的离散效应的研究
Ben Deverett,Duan Li,Theresa R Lii et al.
Ben Deverett et al.
Importance: Ketamine has well-known dissociative, analgesic, and antidepressant properties, but it is unknown whether the neurophysiologic effects that are associated with these properties can be modulated separately from...
Yang Jae Lee,Jürgen Unützer,Robert A Rosenheck et al.
Yang Jae Lee et al.
Ujval S Pathak,Aydan Mehralizade,Terry E Goldberg et al.
Ujval S Pathak et al.
Importance: Dementia develops in individuals with schizophrenia 4- to 20-fold more frequently than in the general population, but its etiology remains unexplained. ...
Interventions for Bereavement: What Works, What Does Not, and What Might [0.03%]
哀伤干预：哪些有效？哪些无效？以及将来可能有用的方法
Charles F Reynolds rd,Holly G Prigerson,M Katherine Shear et al.
Charles F Reynolds rd et al.
Shaddy K Saba,William B Weeks
Shaddy K Saba
Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial [0.03%]
米塔扎平治疗甲基苯丙胺使用障碍的随机临床试验
Rebecca McKetin,Steven Shoptaw,Lucy Saunders et al.
Rebecca McKetin et al.
Importance: Methamphetamine use disorder is a global health challenge for which there are no approved pharmacotherapies. The safety and effectiveness of mirtazapine, a promising candidate for methamphetamine use disorder,...